 NEW YORK, Dec. 18, 2020 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a distribution agreement with Swixx BioPharma AG Swixx to be the exclusive distributor of the Companys antibodies, DANYELZA naxitamab-gqgk for the treatment of patients with relapsedrefractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNSleptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia. DANYELZA naxitamab-gqgk 40mg10mL was approved by the U.S. Food and Drug Administration FDA on November 25, 2020 and is indicated, in combination with granulocyte-macrophage colony-stimulating factor GM-CSF, for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. The Company plans to resubmit its BLA to the FDA for omburtamab by the end of 2020 or in early 2021. 